BioTheranostics
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Medicare Expands Coverage for Hologic's Biotheranostics Breast Cancer Test
The firm said that the expanded coverage provides more women with access to a test that helps determine whether extended endocrine therapy is appropriate.
Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Hologic to Acquire Molecular Diagnostics Firm Biotheranostics for $230M
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.